Navigation Links
Cytel and Medelis Present an Educational Webinar April 7: Transforming Oncology Development with Adaptive Studies
Date:3/24/2011

CAMBRIDGE, Mass. and PHOENIX, March 24, 2011 /PRNewswire/ -- Cytel, a leading provider of adaptive clinical trial services and software, jointly announced with oncology-focused CRO Medelis, the opening of registration for their April 7 webinar "Transforming Oncology Development With Adaptive Studies".

Over 50% of confirmatory clinical studies today end in failure – a distressing reality, especially for oncologists and developers of cancer treatments. Fortunately, increasing use of validated adaptive designs is helping reverse this discouraging trend.

With their improved probability of successful outcome, adaptive trials are increasingly proposed and accepted by international regulatory agencies. Download the FDA's guidance at: www.fda.gov, search: "download adaptive guidance".

Bridging the gap between statistical innovations and clinical reality, the webinar program will educate all oncology treatment stakeholders: study sponsors, their investors, the medical community, and regulators. The webinar centers on the breakthrough adaptive Promising Zone "de-risking" strategy now accepted for pivotal phase 3 development studies.

The April 7 webinar speakers: noted oncology advisor Dr. John Grous from Medelis and Cytel President and Co-Founder Cyrus Mehta, PhD. Together, they'll examine two actual, adaptive confirmatory studies currently underway.

DownloadReferencePublicationsRecommended webinar references include the U.S. Food and Drug Administration's Adaptive Trials Guidance, providing biopharmaceutical study sponsors the established metrics to confidently utilize adaptive methods. The recent peer-reviewed publication Adaptive Increase in Sample Size when Interim Results are Promising documents the underlying Promising Zone statistical technique, adaptive Sample Size Re-estimation.

AbouttheSessionTransforming Oncology Development With Adaptive StudiesThursday, April 7th, 201111:00 AM – 12:00 PM EDTRegister free at: http://bit.ly/cytelwebinar AboutCytelCytel Inc. is a leading provider of clinical trial services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets.

Cytel pioneered the statistical and computational science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider.

AboutMedelisMedelis is an oncology focused CRO with the depth of expertise and agility to

deliver accurate results quickly.

From our advisory board to our project managers and CRAs, Medelis offers deep experience in every facet of the oncology drug development process at all levels of our organization.


'/>"/>

SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Dr. Daniel Von Hoff presented with top genomics award from Scripps
2. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
3. Tip sheet: Caltech researchers presenting at AAAS
4. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
5. Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India
6. 23andMe presents top 10 most interesting genetic findings of 2010
7. Colossal fossil: Museums new whale skeleton represents decades of research
8. Portraits of the Mind author to present a visual history of the brain at public event in New York
9. Bioenergy III Conference: Present and New Perspectives on Biorefineries
10. Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
11. Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology: